3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
34
HER2-positive Breast Cancer
5
Neoplasms
4
Brain Neoplasms
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Meningeal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
Central Nervous System Diseases
1
Breast Diseases
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anatomic Stage IA Breast Cancer AJCC v8
1
Interventions
Trastuzumab
2
tucatinib
1
sagopilone
1
pembrolizumab
1
glutathione pegylated liposomal doxorubicin
1
elacestrant
1
abemaciclib
1
RAD1901
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Diseases
×
tucatinib
×
Breast
×
Clear all
NCT04512261
2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2
Withdrawn